Recent clinical results suggest that higher anti‐tumor efficacy may be achieved with internalizing monoclonal antibodies (MAbs) at lower toxicity when labeled with Auger‐electron, as compared to conventional β‐emitters. The aim of our study was to compare the toxicity and anti‐tumor efficacy of the 125I‐labeled internalizing MAb, CO17‐1A, with its 131I‐labeled form in a human colon cancer model in nude mice. Biodistribution studies were performed in nude mice bearing s.c. human colon cancer xenografts. For therapy, the mice were injected either with unlabeled 125I‐ or 131I‐labeled CO17‐1A at equitoxic doses. Control groups were left untreated, were given a radiolabeled isotype‐matched irrelevant antibody or a tumor‐specific, but noninternalizing antibody. The maximum tolerated activities (MTD) of 131I‐ and 125I‐CO17‐1A without artificial support were 300 μCi and 3 mCi, respectively. Myelotoxicity was dose‐limiting; bone marrow transplantation allowed for an increase of the MTD to 400 μCi of 131I‐17‐1A, whereas the MTD of 125I‐17‐1A with bone marrow support had not been reached at 5 mCi. Whereas no significant therapeutic effects were seen with unlabeled CO17‐1A, tumor growth was retarded with 131I‐CO17‐1A. With the 125I‐label, however, therapeutic results were clearly superior. In contrast, no significant difference was observed in the therapeutic efficacy of the 131I‐ vs. 125I‐labeled, noninternalizing antibodies. Our data indicate a superiority of Auger‐electron emitters, such as 125I, as compared to therapy with conventional β‐emitters with internalizing antibodies. The lower toxicity of Auger emitters may be due to the short path length of their low‐energy electrons, which can reach the nuclear DNA only if the antibody is internalized (as is the case in antigen‐expressing tumor tissue, but not in the stem cells of the red marrow). Int. J. Cancer 76:738–748, 1998.© 1998 Wiley‐Liss, Inc.